Metrics as of 10/15/2026, 11:40 PM (Berlin time), refresh in progress.
Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III…
1D
+0.9%
1W
-11.5%
1M
-37.8%
6M
-18.4%
YTD
+20.6%
1Y
+6.5%
2Y
-39.8%
5Y
-70.7%
10Y
–
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~9% stronger price swings than usual
PRICE TARGET LOW
US$8.00
CONSENSUS
US$8.00
MEDIAN
US$8.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 23/09/2026
P/E
-4.65
P/B
7.65
EV/EBITDA
-4.7
RETURN ON EQUITY
-36.0%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
76.2%
FLOAT SHARES
91,975,657
AVG. DAILY VOLUME (30D)
1,535,702
Cardiol Therapeutics Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is David G. Elsley, the company employs around 18 people.
The IPO was on 15/01/2019; the stock trades on NASDAQ under the ticker CRDL.
2 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$8.00, ranging from US$8.00 to US$8.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 9% stronger than usual.
No, Cardiol Therapeutics currently does not pay a dividend.
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
Clicking "Analyze stock" lets five strategies assess Cardiol Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.